Ann: Dimerix Successfully Passes Efficacy Interim Analysis, page-78

Hi @vintage & Everyone,

Talking about recruitment numbers so far, if you go back to the discussion recently on the weekend, OR just very shortly now. 94 patients so 94/144.

I am pretty sure they could have recruited more onto existing trial sites if they wanted to, but this isn’t the point. It’s intent to treat populations, so now China, Malaysia more countries in EU, and then VERY importantly, the PAEDIATRIC population that was dependent on this Interim analysis to commence in 12yo and above age group (which is the norm to start with) on FDA Approval in a Rare Disease trial. So after the general happiness of this morning before the TH we should probably be also looking at the possible added benefits that maybe some don’t understand yet, unless you have been staring this stuff in the face for a long time.

Have a great afternoon everyone.